Nashville, TN 的 黑色素瘤 臨床試驗
33 項針對 黑色素瘤 的研究正在 Nashville（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
招募中1 期
- Tennessee Oncology, Nashville
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
招募中1/2 期
- Sarah Cannon Research Institute, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
招募中2 期
- SCRI Oncology Partners, Nashville
A Study of BI 3810944 in Patients With Advanced Cancer
招募中1 期
- Tennessee Oncology, PLLC - Elliston Place Plaza DDU, Nashville
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
招募中1 期
- Sarah Cannon Research Institute- Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
招募中3 期
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Tennessee Oncology, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
招募中1/2 期
- Vanderbilt University Medical Center, Nashville
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
招募中3 期
- SCRI Oncology Partners, Nashville
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
招募中3 期
- Vanderbilt University/Ingram Cancer Center, Nashville
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
招募中1/2 期
- Sarah Cannon Research Institute, Nashville
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
招募中1 期
- Sarah Cannon Research Institute, Nashville
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
招募中1/2 期
- Sarah Cannon Research Institute Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Institute, Nashville
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
招募中1 期
- Sarah Cannon Research Institute-Tennessee Oncology, Nashville
Project: Every Child for Younger Patients With Cancer
招募中觀察性研究
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
招募中1/2 期
- Vanderbilt University Medical Center, Nashville
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
招募中1/2 期
- Tennessee Oncology, PLLC, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
招募中1/2 期
- SCRI Oncology Partners, Nashville
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
招募中1 期
- Tennessee Oncology, Nashville
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
招募中1/2 期
- Sarah Cannon Research Institute, Nashville
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
招募中1/2 期
- The Sarah Cannon Research Institute/Tennessee Oncology, Nashville
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
招募中1/2 期
- Sarah Cannon Research Institute, Nashville
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
招募中
- Vanderbilt-Ingram Cancer Center, Nashville
Neoadjuvant Darovasertib in Primary Uveal Melanoma
招募中3 期
- SCRI Oncology Partners, Nashville
- Vanderbilt Eye Institute, Nashville
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
招募中1 期
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
招募中2/3 期
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic), Nashville
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
招募中1 期
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
招募中1/2 期
- Research Site 136, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Nashville
Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
招募中觀察性研究
- Vanderbitl-Ingram Cancer Center, Nashville
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
招募中1/2 期
- Sarah Cannon Research Institute, Nashville
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
招募中1/2 期
- Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
其他城市的 黑色素瘤 試驗
- Houston, TX59 項研究
- New York City, NY38 項研究
- Los Angeles, CA34 項研究
- Pittsburgh, PA31 項研究
- Boston, MA26 項研究
- Philadelphia, PA23 項研究
- San Francisco, CA22 項研究
- St. Louis, MO21 項研究
- Durham, NC21 項研究
- Atlanta, GA21 項研究
- Columbus, OH21 項研究
- Salt Lake City, UT21 項研究
Nashville 的其他研究
- 非小細胞肺癌97 項研究
- 乳癌81 項研究
- 轉移性癌症70 項研究
- 大腸直腸癌69 項研究
- 癌症（所有類型）65 項研究
- 卵巢癌49 項研究
- 前列腺癌43 項研究
- 肺癌40 項研究
- 頭頸部鱗狀細胞癌39 項研究
- 胰臟癌39 項研究
- 子宮內膜癌38 項研究
- 多發性骨髓瘤32 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。